Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-176
- Development stage
- Phase 2
- Lead developer
- Laboratorios Sophia
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
PRO-176 is an ophthalmic 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)-based nanoemulsion developed by Laboratorios Sophia, SA de CV. It is composed of a novel oily phase of castor oil and DMPC, and incorporates propylene glycol. The drug is indicated for the treatment of dry eye disease (DED) by supplementing lipids to the tear film, maintaining aqueous-like dispersion, and reducing tear evaporation. The lipidic phase acts as a surfactant, aiding in the dissemination of nonpolar lipids in the aqueous component of tears, while propylene glycol modifies tear film viscosity.
- Brand names
- Nanodrop
Beyond the preview
Go deeper on PRO-176.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-176.